DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS

Steven De Vleeschouwer(KU Leuven), Michael Sabel(Düsseldorf University Hospital), Marion Rapp(Düsseldorf University Hospital), Walter Stummer(University of Münster), Rüdiger V. Sorg(Düsseldorf University Hospital), Hans‐Jakob Steiger, Stefaan Van Gool(Centrum für Integrierte Onkologie)

Neurosurgery

November 1, 2006

10.1227/01.neu.0000245595.38957.3e

Cited by 67

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

|The Lancet Oncology|2006|3.4k

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

|Neurosurgery|2008|1k

Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients

|Journal of neurosurgery|2000|880

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

|The Lancet|2019|581

What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

|Neurosurgery|2015|368